Skip to main content

December 2018, Vol 8, No 12

The BCL2 Gly101Val mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia. Read More ›






Business intelligence is the process of collecting data from disparate systems—internal and external—and turning it into information that is meaningful and actionable toward achieving strategic goals. Read More ›



The McKesson value-based care team employs a combination of tactics to help practices in The US Oncology Network achieve success in the Merit-Based Incentive Payment System (MIPS). One of the challenges with the new MIPS program is the need to focus on the current year’s performance, while taking steps to ensure that practices are successful in future years. Read More ›

Page 1 of 2